Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc.

Bullboard Posts

Comment by duckdog68on May 09, 2016 11:56am

409 Views

Post# 24854190

RE:RE:RE:Omnio

Much speculation about other Pg indications. Just reposting this list from the Omnio.se website in case anyone missed it.
dd

duckdog68 wrote:

Mimibegalo wrote:
And he said that this deal has secured to PLI pg market World wide for this type of wounds.
He added that more applications for Pg are under study... but PLI wont discuse any now. but he said that it will be definitlty something worth looking at.

From the Omnio.se website, other indications that Pg may apply to are listed as follows:

OTHER INDICATIONS

In addition to wound healing, there are several other symptoms where stimulation of the plasminogen signaling pathways has shown benefit in pre-clinical trials:

-Enhancing the host defense against infections by antibiotic resistant bacteria   (Omnio patent)

-Treatment of periodontitis   (Omnio patent)

-Repair of tympanic membrane (ear drum) perforation   (Omnio patent)

-Repair of wounds caused by radio therapy (Omnio patent application)

-Protection from damage by radio therapy (Omnio patent application)

-Treatment of patients suffering from plasminogen deficiency (shown independently of Omnio)

GLTA, dd